# Ardent Health account plan

> Ardent Health runs 30 acute care hospitals in six U.S. states, with 2025 revenue of $6,324.3 million and about 25,200 employees.

## At a glance

Ardent Health, Inc., based in Brentwood, Tennessee and listed on the NYSE (ARDT) since its July 2024 IPO, operates acute care hospitals, clinics and other healthcare facilities in mid-sized urban markets. At December 31, 2025 it ran 30 hospitals with 4,281 licensed beds and more than 280 sites of care across Texas, Oklahoma, New Mexico, New Jersey, Idaho and Kansas, mostly through joint ventures with academic and not-for-profit health systems. 2025 revenue was $6,324.3 million (+6.0%), net income $230.1 million and Adjusted EBITDA $545.0 million, with about 25,200 employees. It is a NYSE controlled company whose controlling stockholder is EGI-AM, and it runs on a single system-wide Epic instance.

## Business units

- **Texas** (35.7% of 2025 revenue): Thirteen hospitals with 1,436 licensed beds in three systems: UT Health East Texas in Tyler (a JV with UTHSCT), BSA Health System in Amarillo with the largest local market share, and Seton Medical Center Harker Heights in Killeen.
- **Oklahoma: Hillcrest HealthCare System** (23.6% of 2025 revenue): Eight leased hospitals in Tulsa with 1,173 licensed beds and 82 sites of care, second in its market with 24.5% share.
- **New Mexico: Lovelace Health System** (17.0% of 2025 revenue): Five leased hospitals serving Albuquerque and Roswell with 619 beds, third in market share; the source of most 2025 professional liability losses.
- **New Jersey: Hackensack Meridian Medical Centers** (10.2% of 2025 revenue): Two JV-operated hospitals, Mountainside and Pascack Valley, with 476 beds and the largest market share (51.7%) in Montclair/Westwood.
- **Idaho: Portneuf Medical Center**: One hospital in Pocatello with 199 beds and 58.4% market share, run as a 77.0% Ardent JV.
- **Kansas: UKHS St. Francis Medical Center**: One hospital in Topeka with 378 beds; in September 2026 Ardent agreed to sell its 70.5% stake to the University of Kansas Hospital Authority for $58.4 million, expected to close in Q4 2026.

## Strategic priorities

- **IMPACT cost programme**: A multiyear efficiency programme that delivered $5 million of savings in 2025 and is expected to deliver at least $70 million in 2026, covering workforce productivity, supply chain, drug lists, AI efficiencies and revenue cycle tools.
- **Organic growth in core markets**: Capacity IQ directs growth to the service lines with the most opportunity, with focus on cardiology and women's and children's; a centralized patient logistics hub saw call volume rise 15% in Q3 2026.
- **Ambulatory expansion**: Ardent captures 11% of its current markets' spend but only 3% of ambulatory and outpatient, which it sees as the main share-gain opportunity; it acquired or built over 25 urgent care and ASC facilities in two years.
- **Payer recontracting**: Using price-transparency data, Ardent is renegotiating rates it sees as below the 50th percentile; it is 85% contracted for 2027 and 75% for 2028.
- **Disciplined capital deployment**: Portfolio review, buybacks and M&A in mid-sized urban markets with above-average population growth, with or without JV partners.

## Latest results

In Q3 2026, total revenue was $1,624.9 million (+3.1%) and Adjusted EBITDA $137.7 million versus $45.3 million a year earlier, when a professional liability reserve increase weighed. Net income attributable to Ardent was $44.5 million against a loss of $23.5 million. Adjusted admissions rose 2.9%, while surgeries fell 1.9%, and contract labor fell 44.8%. For the nine months, revenue was $4,849.0 million (+2.7%) and Adjusted EBITDA $376.7 million. 2026 Adjusted EBITDA guidance was raised to $500-535 million, with revenue biased toward the lower end of $6.4-6.7 billion.

## Investments and deals

- **Capital expenditure**: Capex was $211.9 million in 2025; the 2026 range was cut to $210-250 million without affecting maintenance or growth commitments.
- **Urgent care acquisition**: 18 urgent care clinics in New Mexico and Oklahoma acquired on January 1, 2025 for $27.5 million.
- **Virtual care and ambient AI**: Virtual nursing with hellocare.ai is being deployed in over 2,000 hospital rooms, and the ambient documentation tool passed 1.5 million encounters.
- **Kansas divestiture**: Sale of the 70.5% stake in St. Francis to its JV partner for $58.4 million at an 11x EBITDA multiple, improving margins by 40 basis points.
- **ERP conversion and refinancing**: ERP conversion costs were $11.7 million in the first nine months of 2026; the Term Loan B was refinanced in September 2025 to 2032.

## Challenges and risks

- **Medicaid and ACA changes**: The OBBBA tightens Medicaid eligibility and caps state directed payments, enhanced ACA exchange subsidies expired at end-2025 with a $35 million 2026 headwind, and Medicaid supplemental payment revenue is expected to decline.
- **Professional fees and labor**: Professional fees rose to 20.1% of nine-month 2026 revenue from 18.7%, and nurse shortages and strained hospital-based physician contractors remain labor risks.
- **Soft surgical volumes**: Surgeries fell 1.2% in the first nine months of 2026 as patients face higher deductibles and co-pays.
- **Liability and litigation**: New Mexico drove $51.3 million of 2025 professional liability losses, a suit settled for $40.0 million in 2026, and a securities class action is pending.
- **Payer denials**: Denials remain elevated, and payer negotiations have become more contentious.

## What leadership says

> "IMPACT is not a one-year project. It's a multi-year strategic imperative." — Dave Caspers, President and CEO, Q2 2026 earnings call, August 5, 2026.

> "sharper operational execution is my highest priority" — Dave Caspers, President and CEO, Q2 2026 earnings call, August 5, 2026.

> "We are patient and thoughtful and prepared." — Dave Caspers, President and CEO, On M&A and distressed assets, Q3 2026 earnings call, November 5, 2026.

> "you can't defer care forever" — Alfred Lumsdaine, CFO, On volume weakness, Q2 2026 earnings call, August 5, 2026.


## Where a supplier can help

- **Cost-saving projects under IMPACT**: The IMPACT programme's conveyor belt of projects in supply chain, drug lists, AI efficiencies and revenue cycle invites suppliers with measurable savings.
- **Clinical AI and virtual care**: The virtual nursing rollout and ambient documentation, live for about 900 providers, open room for complementary clinical technology.
- **Revenue cycle and denials**: Elevated denials and a reconstituted revenue integrity unit point to denial management and payer analytics tools.
- **Ambulatory build-out**: The ambulatory share-gain priority and urgent care and ASC growth create demand for construction, imaging equipment and outpatient operations.
- **Workforce and hiring**: The push for faster hiring so contract labor does not return favours recruiting and workforce management providers.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Ardent Health, Inc. Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1756655/000162828026018174/ardt-20251231.htm)

Annual report · 2026-03-16

- Ardent Health (NYSE: ARDT, Brentwood, Tennessee) runs 30 acute care hospitals, more than 280 sites of care and over 2,000 employed or affiliated providers in eight mid-sized urban markets across six states (Texas, Oklahoma, New Mexico, New Jersey, Idaho, Kansas), as of December 31, 2025.
- FY2025: total revenue $6,324.3 million (+6.0%), net income $230.1 million, Adjusted EBITDA $545.0 million (vs $498.5 million in 2024); adjusted admissions +2.3%, net patient service revenue per adjusted admission +3.5%.
- One reportable segment (healthcare services); revenue by state: Texas 35.7%, Oklahoma 23.6%, New Mexico 17.0%, New Jersey 10.2%. Payer mix: other managed care 44.3%, Medicare 38.6%, Medicaid 9.6%, self-pay and other 5.6%.
- Joint-venture model with academic medical centers, not-for-profit systems, physicians and a community foundation: 18 of 30 hospitals are JV-operated; JV entities produced $1,843.1 million, 29.1% of 2025 revenue. Ardent is always majority owner and day-to-day operator.
- Single system-wide Epic instance (Epic "Gold Stars 9"); AI and virtual nursing, BioIntelliSense BioButton used on more than 77,000 patients in 2025; revenue cycle outsourced to Ensemble (86.6% of 2025 revenue collected through that contract); purchasing through HealthTrust.
- Strategy: build leading positions in existing markets (ambulatory sites, high-acuity services, physician recruitment, transfer centers, value-based care) and enter new mid-sized markets, mainly through JVs with not-for-profit and academic systems; about 350 target markets identified.
- Cost pressures in 2025: professional fees rose to 18.9% of revenue; $51.3 million of professional liability losses, mostly New Mexico; $42.6 million revenue reduction from a change in collectability estimate. Medicaid supplemental payment revenue reached $707.5 million.
- Balance sheet at year-end 2025: cash $709.6 million, liquidity $1,004.2 million, net leverage 0.8x, lease-adjusted net leverage 2.5x; capex $211.9 million; Term Loan B refinanced to 2032 at SOFR + 2.25%.
- Key risks: OBBBA Medicaid cuts and work requirements, expiry of enhanced ACA exchange subsidies (expected to hurt 2026), payer denials, staffing and hospital-based physician costs, concentration in Texas and Oklahoma, Ventas master lease covenants, a securities class action filed January 7, 2026; EGI-AM is the controlling stockholder.

### [Ardent Health, Inc. Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1756655/000162828026071073/ardt-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 (quarter to September 30, 2026): total revenue $1,624.9 million, up 3.1%; net income $63.4 million vs $1.2 million a year earlier; net income attributable to Ardent $44.5 million vs a $23.5 million loss; Adjusted EBITDA $137.7 million vs $45.3 million.
- Volumes: adjusted admissions +2.9%, admissions +0.1%, ER visits +1.7%, total surgeries -1.9%; net patient service revenue per adjusted admission +0.7% (down 2.0% excluding the prior-year $42.6 million estimate change, mainly from $29.6 million lower Medicaid supplemental payments).
- Nine months 2026: revenue $4,849.0 million (+2.7%), net income $156.6 million, Adjusted EBITDA $376.7 million vs $313.3 million.
- Costs: salaries and benefits fell to 39.9% of Q3 revenue from 42.9%, down $29.0 million with contract labor down 44.8%; professional fees rose to 20.2% of revenue on hospital-based provider costs, software amortization and consulting.
- Restructuring: $21.5 million of nine-month termination benefits for position eliminations and executive leadership departures, plus $10.7 million of advisory fees.
- Portfolio: definitive agreement on September 28, 2026 to sell the 70.5% stake in St. Francis (Topeka, Kansas) to the University of Kansas Hospital Authority for $58.4 million, closing expected in Q4 2026.
- Liquidity at September 30, 2026: cash $766.2 million, available liquidity $1,009.8 million, net leverage 0.8x, lease-adjusted 2.5x; $24.0 million of share repurchases in nine months; a $40.0 million professional liability settlement payable before end-2026.
- Policy: OBBBA Medicaid and ACA changes, the expiry of enhanced exchange subsidies (hurting 2026) and the $50 billion Rural Health Transformation Program, for which Ardent is eligible in all its states.

### [Ardent Health Q3 2026 earnings call transcript](https://www.tradingkey.com/news/transcripts/262288691-)

Executive talk · Dave Caspers, President and Chief Executive Officer · 2026-11-05

- First full quarter under Dave Caspers as CEO: Q3 2026 revenue $1.62 billion, Adjusted EBITDA $138 million, operating cash flow $122 million; adjusted admissions +2.9%, surgeries -1.9% (about half from deliberate rationalization of lower-margin service lines).
- 2026 Adjusted EBITDA guidance raised to $500-535 million from $485-535 million; revenue biased to the low end of $6.4-6.7 billion; capex range cut to $210-250 million from $225-265 million.
- IMPACT, a multiyear efficiency program, is on track for at least $70 million of savings in 2026 ($5 million in 2025), with a $20-25 million carry-over into 2027; Caspers calls it "a way of life".
- SW&B fell 4.3% to 39.9% of revenue; contract labor spend down 45% (2.0% of SW&B vs 3.5%); professional fee growth slowed to 7.4% from 12.9% in Q1.
- Portfolio review led to the sale of the Kansas hospital stake to the JV partner at 11x EBITDA, adding 40 basis points to margin; M&A focus is system-level assets in growing mid-sized urban markets, with a growing list of distressed assets available.
- Payer recontracting using price-transparency data: 85% contracted for 2027 and 75% for 2028; negotiations described as "a little more contentious".
- Technology: ambient documentation reached 1.5 million encounters with about 900 of 2,000 providers live and about an 8% productivity gain; enterprise virtual care rollout speeds discharges.
- Balance sheet: $766 million cash, $1.1 billion debt, net leverage 0.8x (lease-adjusted 2.5x); $11 million of buybacks in Q3, $48 million authorization left.
- 2027 headwinds named: Medicaid work requirements, exchange attrition, higher deductibles and co-pays; exchange impact for 2026 tracking the $35 million estimate.

### [Ardent Health Q2 2026 earnings call transcript](https://allmind.ai/earnings/event/2944199)

Executive talk · Dave Caspers, President and Chief Executive Officer · 2026-08-05

- First earnings call for Dave Caspers as President and CEO (Q2 2026, August 5, 2026): revenue $1.62 billion, Adjusted EBITDA $115 million; operating cash flow $197 million vs $117 million.
- Surgeries were down 5% and admissions 2% in April-May before recovering in June; for the quarter surgeries -2.9%, admissions -1%, adjusted admissions +2.5%.
- 2026 Adjusted EBITDA guidance of $485-535 million maintained; revenue now biased to the low end of $6.4-6.7 billion; about $25 million volume headwind offset by $20-30 million of actions.
- IMPACT savings target raised twice, from $40 million to $55 million to over $70 million for 2026, helped by removing managerial layers ($15-20 million in 2026, $30-35 million annualized).
- Payer contracting with price-transparency data: many rates below the 50th percentile; one June renewal adds $5-10 million to 2026 Adjusted EBITDA.
- SW&B grew only 0.7% and contract labor spend fell 42%; professional fee growth slowed to 10.4%.
- Caspers' priorities: consistent results, EBITDA growth, capital deployment, "one team, one plan, and one standard"; service lines focused on cardiology and women's and children's, guided by Capacity IQ; lower-margin ENT and ophthalmology moved out of hospitals.
- Technology: hellocare.ai virtual nursing (58% of discharges in Texas and Idaho in June, to be deployed in over 2,000 rooms) and ambient listening with a better-than-mid-single-digit productivity gain; Epic and Ensemble partnerships.
- Balance sheet: cash $724 million, liquidity $992 million, net leverage 0.8x; $13 million of buybacks in Q2.

## Questions about Ardent Health

### What does Ardent Health do?

Ardent Health operates 30 acute care hospitals and more than 280 sites of care in mid-sized urban markets across six U.S. states, mostly through joint ventures with academic and not-for-profit health systems.

### What is Ardent Health's revenue?

2025 revenue was $6,324.3 million, and 2026 revenue is guided toward the lower end of $6.4-6.7 billion.

### How many employees does Ardent Health have?

Ardent had about 25,200 employees at the end of 2025 and over 2,000 employed and affiliated providers.

### What is Ardent Health's strategy?

Margins through operational excellence and the IMPACT programme, organic growth in core markets and services, and disciplined capital deployment including M&A.

### Who leads Ardent Health?

Dave Caspers is President and CEO, and Alfred Lumsdaine is CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
